Impairment, disability, and satisfaction outcomes after lower-extremity botulinum toxin a injections for children with cerebral palsy

Pediatric Physical Therapy

Volumn 14, Issue 3, 2002, Pages 132-144

  Fragala, Maria A ^a   O'Neil, Margaret E ^a   Russo, Kara J ^a   Dumas, Helene M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Articular; Botulinum toxins administration and dosage; Botulinum toxins therapeutic use; Cerebral palsy drug therapy; Child; Muscle spasticity drug therapy; Parents; Quality of life; Range of motion; Recovery of function; Treatment outcome

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISABILITY; FEMALE; HANDICAPPED CHILD; HUMAN; INJECTION SITE; LEG MOVEMENT; MALE; MODIFIED ASHWORTH SCALE; PASSIVE MOVEMENT; PATIENT SATISFACTION; QUALITY OF LIFE; RATING SCALE; SPASTICITY; TREATMENT OUTCOME;

EID: 0036741751     PISSN: 08985669     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001577-200214030-00003     Document Type: Article

References (49)

1. Hayes M, McEwen IR, Lovett D, et al. Next step: survey of pediatric physical therapist's educational needs and perceptions of motor control, motor development and motor learning as they relate to services for children with developmental disabilities. Pediatr Phys Ther. 1999;11:164-182.
2. Olney S, Wright M. Cerebral palsy. In: Campbell S, ed. Physical Therapy for Children. Philadelphia, PA: WB Sanders; 2000:533-570.
3. Cosgrove A, Corry I, Graham H. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol. 1994;36:386-396.
4. Koman L, Mooney JI, Smith B, et al. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop. 1993;13:489-495.
5. Heinen F, Wissel J, Philipsen A, et al. Interventional neuropediatrics: Treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics. 1997;28:307-313.
6. Koman L, Mooney II, Smith B, et al. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop. 1994;14:299-303.
7. Delgado M. The use of botulinum toxin A in children with cerebral palsy: a retrospective study. Eur J Neurol. 1999;6:S11-S18.
8. Boyd R, Graham J, Nattrass G, et al. Medium-term response characterization and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy. Eur J Neurol. 1999;6:537-545.
9. Bakheit A, Severa S, Cosgrove A, et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol. 2001;43:234-238.
10. American Physical Therapy Association. Guide to physical therapist practice, second edition. Phys Ther. 2001;81:519-528.
11. Calderon-Gonzalez R, Calderon-Sepulveda R, Rincon-Reyes M, et al. Botulinum toxin A in management of cerebral palsy. Pediatr Neurol. 1994;10:284-288.
12. Corry I, Cosgrove A, Duffy C, et al. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomized prospective trial. J Pediatr Orthop. 1998;18:304-311.
13. Wisse J, Heinen F, Schenkel A, et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment. Neuropediatrics. 1999;30:120-124.
14. Wong V. Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol. 1998;18:124-131.
15. Bohannon R, Smith M. Interrater reliability of a Modified Ashworth Scale of muscle spasticity. Phys Ther. 1987;67:206-207.
16. Massin M, Allington N. Role of exercise testing in the functional assessment of cerebral palsy children after botulinum A toxin injection. J Pediatr Orthop. 1999;19:362-365.
17. Corry IS, Cosgrove AP, Duffy CM, et al. Botulinum toxin A as an alternative to serial casting in the conservative management of equinus in cerebral palsy. Dev Med Child Neurol. 1995;37:S20-S21.
18. Molenaers G, Desloovere K, Fyssen M, et al. Botulinum toxin type A treatment of cerebral palsy: an integrated approach. Eur J Neurol. 1999;6:S51-S57.
19. Wissel J, Muller J, Baldauf A, et al. Gait analysis to assess the effects of botulinum toxin type A treatment in cerebral palsy: an open-label study in 10 children with equinus gait pattern. Eur J Neurol. 1999;6: S63-S67.
20. Thompson N, Baker R, Cosgrove A, et al. Musculoskeletal modeling in determining the effect of botulinum toxin on the hamstrings of patients with crouch gait. Dev Med Child Neurol. 1998;40:622-625.
21. Ruiz P, Pascual I, Bernardos S. Progressive response to botulinum A toxin in cerebral palsy. Eur J Neurol. 2000;7:191-193.
22. Corry I, Cosgrove A, Duffy C, et al. Botulinum toxin A in hamstring spasticity. Gait Posture. 1999;10:206-210.
23. Sutherland D, Kaufman K, Waytt M, et al. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture. 1999;10:1-9.
24. Boyd R, Pliatsios V, Starr R, et al. Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol. 2000;42:32-41.
25. Koman L, Mooney JI, Smith B, et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop. 2000;20:108-115.
26. Koman L, Smith B, Tingey C, et al. The effect of botulinum toxin type A injections on the natural history of equinus foot deformity in paediatric cerebral palsy patients. Eur J Neurol. 1999;6:519-522.
27. Ubhi T, Bhakta B, Ives H, et al. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child. 2000;83:481-487.
28. Mall V, Heinen F, Kirschner J, et al. Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure. J Child Neurol. 2000;15:214-217.
29. Gooch J, Sandell T. Botulinum toxin for spasticity and athetosis in children with cerebral palsy. Arch Phys Med Rehabil. 1996;77:508-511.
30. Mall V, Heinen F, Linder M, Philipsen A, Korinthenberg R. Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports. Pediatr Rehabil. 1997;1:235-237.
31. Flett P, Stern L, Waddy H, et al. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health. 1999;35:71-77.
32. Heinen F, Linder M, Mall V, et al. Adductor spasticity in children with cerebral palsy and treatment with botulinum toxin type A: the parent's view of functional outcome. Eur J Neurol. 1999;6:S47-S50.
33. American Academy of Orthopedic Surgeons. Joint Motion: Method of Measuring and Recording. Chicago, IL: American Academy of Orthopedic Surgeons; 1965.
34. Portney L, Watkins M. Foundations of Clinical Research: Applications to Practice. Upper Saddle River, NJ: Prentice-Hall, Inc; 2000.
35. Sackett D. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1986;89:25-35.
36. Daniels L, Worthingham C. Muscle Testing Techniques of Manual Examination. 4th ed. Philadelphia, PA: WB Saunders; 1980.
37. Stuberg W, Fuchs R, Miedaner J. Reliability of goniometric measurements of children with cerebral palsy. Dev Med Child Neurol. 1988;30:657-666.
38. Katz K, Rosenthal A, Yosipovitch Z. Normal ranges of popliteal angle in children. J Pediatr Orthop. 1992;12:229-231.
39. Haley S, Coster W, Ludlow L, et al. Pediatric Evaluation of Disability Inventory. Boston, Mass: New England Medical Center Hospitals, Inc., and PEDI Research Group; 1992.
40. McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires. 2nd ed. New York: Oxford University Press; 1996.
41. Law M, Baptiste S, McColl M, et al. The Canadian Occupational Performance Measure: an outcome measure for occupational therapy. Can J Occup Ther. 1990;57:82-87.
42. Law M, Polatajko H, Pollock N, et al. Pilot testing of the Canadian Occupational Performance Measure: clinical and measurement issues. Can J Occup Ther. 1994;61:191-197.
43. Long T. The use of parent report measures to assess infant development. Pediatr Phys Ther. 1992;4:74-77.
44. King S, Rosenbaum P, King G. The Measure of Processes of Care: MPOC, A Means to Assess Family-Centered Behaviors of Health Care Providers. Ontario, Hamilton, Canada: Neurodevelopmental Clinical Research Unit; 1995.
45. Fosang A, Thomason P, McCoy A. Parent perception is a valid measure to evaluate changes in physical function in the child with cerebral palsy. Dev Med Child Neurol. 1998;40:8.
46. Barry M, Labright A. Use of Canadian Occupational Performance Measure as an outcome measure for intrathecal Baclofen therapy. Pediatr Phys Ther. 1996;8:183-184.
47. Ottenbacher K. Evaluating Clinical Change: Strategies for Occupational and Physical Therapists. Baltimore, Md: Williams & Wilkins; 1986.
48. Wolery M, Harris S. Interpreting results of single-subject research designs. Phys Ther. 1982;62:445-452.
49. Leach J. Children undergoing treatment with botulinum toxin: the role of the physical therapist. Muscle Nerve. 1997;20:S194-S207.